Indication

For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):
• in patients with haemolysis with clinical symptom(s) indicative of high disease activity
• in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.

Medicine details

Medicine name:
ravulizumab (Ultomiris)
SMC ID:
SMC2305
Pharmaceutical company
Alexion Pharma UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
Q1 2021
SMC meeting date:
Q1 2021
Patient group submission deadline:
02 November 2020